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The complement peptides C3a and C5a have been shown 
previously to release histamine from human basophils but not 
human lung mast cells. As skin mast cells differ from those of 
the lung in both immunocytochemical and functional prop-
erties, we examined the ability of these anaphylatoxins to 
release preformed and newly generated mediators from 
human dispersed skin mast cells. In concentration-response 
studies, both C3a and C5a released histamine in a concentra-
tion related manner w ith C5a being 40 - 50 times more po-
tent. However, the extent of histamine, 15 - 20%, was con-
siderably less than that released from basophils . This was not 
due to catabolism of the peptides by mast cell proteases, mast 
cell supernatants that contained C5a being effective in re-
leasing basophil histamine. Removal of the C-terminal argi-
nine from C3a and C5a abolished their activity on skin mast 
cells. In time-course studies, histamine release induced by 
C3a and C5a was complete within 15 seconds. Comple-
T he anaphylatoxins C3a and C5a are important media-tors of both allergic and inflammatory reactions. They are formed from the amino-terminus of the a-chain of the third and fifth components of comple-ment, respectively, upon activation of either the clas-
sical or alternative pathway [1,2], and are degraded to their des Arg 
derivatives by removal of the C-terminal arginine by carboxypepti-
dase-N, an enzyme present in normal human serum and extravascu-
lar fluid [3,4] . 
One of the major purported contributions of C3a and C5a to 
inflammation is their potential ability to release histamine and other 
mediators from mast cells and basophils. In preparations of human 
basophils in vitro, C5a, and to a lesser extent C3a [5], stimulates the 
rapid release of histamine, which, in reaching a maximum in less 
than 1 min, is much faster than that induced by anti-IgE, suggesting 
a different mechanism of action [6 - 8]. This difference in stimula-
tory mechanism in human basophils is supported by the observa-
tions that, in contrast to anti-IgE, C5a, even though it is a potent 
stimulator of histamine release, fails to activate the biochemical 
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ment-induced histamine release is a non-cytotoxic process as 
evidenced by 2-deoxy-D-glucose and antimycin A, inhibi-
tors of glycolysis and oxidative phosphorylation, respec-
tively. In contrast to IgE-dependent stimulation, anaphyla-
toxin-induced histamine release from human skin mast cells 
is independent of extracellular calcium. Both C3a and C5a at 
concentrations that induced 10-16% net histamine release 
caused a negligible release of the newly generated mediator, 
PGD2 • The results suggest that C3a and C5a stimulate 
human skin mast cells in a manner similar to substance P and 
related basic secretagogues. However, the activation site for 
C3a and C5a appears to be different to that for substance P as 
the substance p antagonist (D-Pro4, D-Trp7,9,lO) SP 4-11 in-
hibited histamine release stimulated by substance P but not 
that induced by C3a and C5a.] Invest Dermatol1 02:803 - 806, 
1994 
pathways leading to leukotriene C. (LTC.) generation unless the 
cells are primed by prior incubation with interleukin 3 (IL-3) [9,10]. 
Mast cell studies have shown a heterogeneous response. In the rat, 
both C3a and C5a stimulate the release of histamine from peritoneal 
mast cells [11,12], whereas in the mouse C5a releases histamine 
fron; cutane~)Us, but not peritoneal, mast cells [13]. Complement 
pepttdes neither release histamine directly nor enhance IgE-
mediated mediator secretion release from human IWIg mast cells or 
chopped lung fragments [10]. 
In human skin, CSa is a potent inflammatory mediator [14] and is 
be~iev~d to play an important role in the pathophysiol<;lgy of certain 
Sklll disorders and systemic diseases with cutaneous manifestation 
[15,16]. Intradermal injection of C3a and C5a is characterized clini-
cally by a dose-dependent cutaneous wheal and flare response 
[14,17 - 20] with C5a being more potent than C3a. Histologically, 
biopsies from sites of intradermal injection of the anaphylatoxins 
show dense polymorphonuclear neutrophil-rich infiltrates asso-
ciated with leukocytoclasis oedema, dermal mast cell degranulation, 
and the presence within the dermis of metachromatically staining 
granules thought to derive from mast cells [14,17,18,21]. As may be 
expected, C3a des Arg and C5a des Arg are much less potent than 
their parent complement peptides in eliciting cutaneous wheal and 
flare responses in human skin. 
These in vivo studies would suggest that C3a and C5a induce a 
wheal and flare response following stimulation of dermal mast cells, 
a suggestion that is supported by the recent publication by Kubota 
[22] that incubation of dispersed human skin mast cells with C5a 
and C3a results in the release of histamine. The experiments 
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presented on human dispersed s.kin mast cells in this p~per confirm 
this observation, assess the ablhty of punfied preparations of C3a, 
C5a, C3a des Arg, and C5a des Arg to also release newly generated 
mediators and investigate the mechanisms of anaphylatoxin-
induced mediator release. 
MATERIALS AND METHODS 
Materials Eagle's minimum essential medium (MEM) and feta l bovine 
se rum (FES) were obtained from Gibco Europe Ltd., Paisley, Scotland; 
collagenase (type I), hyaluronidase (type I), protease (fraction XIV), sub-
stance P, pencillin/streptomycin, and bovine serum albumin (BSA) from 
Sigma Chemical Company, Poole, Dorset, U.K.; N-2-hydroxyethyl-N-2-
ethanesulphonic acid (HEPES) from BDH Chemicals, Poole, Dorset, U.K.; 
Dextran 110 from Fisons pharmaceuticals, Loughbobough, U.K.; [D-Pro4, 
D_Trp7.9.IOJ SP._II substance P (SPA) from Peninsular Laboratories Europe 
Ltd., St. Helens, Merseyside, U.K. Anti-human IgE was prepared as previ-
ously described [23). HEPES-buffered salt solution (HESS), pH 7.2, con-
tained 137 ruM NaCl, 20 ruM HEPES, 5 mM D-glucose, 2.7 ruM KCl, 0.4 
ruM NaHzPO., and 0.1 % gelatin. Release experiments were carried out in 
HESS supplemented with 1.8 mM CaClz and 0.5 mM MgClz. 
Complement Peptide Preparation Complement peptides C3a and 
CSa were purified from human yeast activated serum as previously reported 
[2,24] . They were demonstrated to be chemically homogeneous by amino 
acid analysis, sodium dodecylsulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and microzone electrophoresis at pH8.6. Cross tachyphylaxis 
experiments using guinea pig ileum indicated that the C3a preparation used 
contained less than 0.002% CSa [25). C leavage of the anaphylatoxins to 
their potentially inactive des Arg derivatives by proteases, particularly car-
boxypeptidase-N, was minimized by the use of surgical gloves and clean 
steri le equipment and the preparation of all buffers in double-distilled water. 
All di lu tions of complement peptides from stock solutions were made using 
sterile 0.9% NaCl saline containing 0.5 mg/ml human serum albumin of 
highest purity as a protein carrier. 
Human Skin Mast Cell Isolation and Activation Mast cells were dis-
persed from human chopped foreskin by enzymatic digestion in MEM con-
taining 1.5 mg/ml collagenase, 0.75 mg/ml hyaluronidase, 0.5 mg/ml 
protease, 100 U /ml penici llin , 100 J.ig/ml streptomycin, and 2 mg/ml bo-
vine serum albumin as previously described [23]. The percentage of mast 
cells in the resulting cell suspension, determined by light microscopy using 
Kimura's stain [26), was 1.1 ± 0.2 X 10' mast cells/ g of skin with a purity of 
4.6 ± 0.4% of the total nucleated cells (both mean ± SEM). The major 
contaminant cells were endothelial cells and fibroblasts. 
Before activation, cells were washed 3 - 4 times in FBS, Ca++ -, Mg++ -free 
HBSS containing 0.1 % gelatin and resuspended in HESS containing 1.8 
ruM Ca++, 0.5 ruM Mg++, and 0.1 % gelatin. Following warming for 10 min 
at 37 · C, 90 pI of cel l suspension, containing approximately 4 X 10' mast 
cells, were added to 10 pI of complement peptide in conical polypropylene 
microfuge tubes. Histamine release reactions were allowed to proceed for 10 
min at 37 · C before termination by addition of 900 J.il of icc-cold Ca++-, 
Mg++ -free HESS. 
To determine the influence of calcium on the histamine release, cells were 
incubated in Ca++ -free medium containing 2 111M ethylene diaminetetra-
acetic acid (EDTA) for 5 min before activation with anaphylatoxins. To 
assess energy requirements, cells were incubated for 15 min at 37"C in 
glucose-free HBSS containing 10 mM 2-deoxy-D-glucose (to inhibit gly-
colysis) and 1 J.lM antimycin A (to inhibit oxidative phosphorylation) before 
activation. 
In exeeriments to assess the effect of the substance P antagonist (D-Pro<, 
T rp7.9. IOJ SP._II on C3a- and CSa-induced histamine release, 81 J.il samples 
of cel l suspension containing approximately 4 X 10' mast cells were first 
incubated for 5 min at 37·C with 9 pI of the antagonist (3, 10,30,50 JIM) 
and then activated for histamine release by addition of 10 pi of CSa (1 pM), 
CSa (1 ,£1M), or substance P (30 JIM). 
Preparation and Activation of Human Basophils Mixed leukocytes 
containing basophils were separated from normal healthy donors fresh 
venous blood by dextran sedimentation [27). Briefly, the 50 ml of blood was 
anticoagulated with 0.5 ml of 0.5 M EDTA and mixed with 10 ml of a 
solution of 3% dextran - 3% glucose in 0.9% sodium cl~l'oride (Dextran 
110), then allowed to sediment for 90 min at room temperature. The upper 
buffy coat layer was removed, cells were separated from thc plasma by 
ccntrifugation at 120 X g for 10 min, washed twice in HBSS buffer, then 
resuspended in HESS containing 1.8 mM CaClz and 0.5 ruM MgClz for use 
in the histamine release assay. 
Assays For histamine assay, supernatants were acidified with trichloro-
acetic acid at a final concentration of 5% for determination of the histamine 
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Figure 1. Concentration-related release of histamine from human skin 
mast cells by complement peptides. A, results for C3a ~) and C3a des Arg 
(0); B, results for CSa (.) and CSa des Arg (0). Results are expressed as mean 
± SEM of four to eight experiments in which spontaneous histamine release 
was 4.5 ± 0.6%. 
content by automated spectrofluorometry [28) . Histamine released by the 
complement peptides is expressed as the percentage of total histamine COIl-
tent, determined by lysis of cells in 5% trichloroacetic acid, and corrected for 
spontaneous histamine release. 
Prostaglandin Dz (PGD z) was measured by using a radioimmunoassay kit 
(Amersham International PLC, Buckinghamshire) according to the manu-
facturer's instructions. In brief, samples and standards were added to 
JH-PGDz, followed by addition ofPGDz anti-serum, and the reaction mix-
ture was incubated overnight at 4 · C. Free tracer was absorbed on dextran-
coated charcoal. Radioactivity of antigen-antibody complexes was measured 
by p-scintillation spectrometry. The limit of detection of PG D z in this assay 
is 3.1 pg/ tube. 
Statistical Analyses Results are expressed as mean ± SEM for the stated 
number of separate experiments. Differences between means were tested for 
significance by using the Student t test for paired data. Differences were 
considered significant when the probability (p) was less than 0.05. 
RESULTS 
Mediator Release Studies Both C3a (0.0001- 50 ,liM) and CSa 
(0.0001-10,liM) caused a shallow concentration-related release of 
histamine when incubated with human skin mast cells for 10 min, 
C5a being approximately 40 - 50 t imes more potent than C3a (Fig 
1). The maximum releases obtained were 14.1 ± 0 .6% (mean ± 
SEM) at 50 ,liM for C3a and 17.4 ± 1.2% at 10 ,liM for C5a (both 
p < 0.0001). Removal of the C-terminal arginine from C3a and 
C5a led to a great reduction in the activity of both anaphylatoxins, 
C3a des Arg (0.0001-10 ,liM) and CSa des Arg (0.0001 - 1 liM) 
releasing only 3 .8 ± 0.6% and 3.2 ± 1.3%, respectively, at the 
highest concentrations used (Fig 1). 
Kinetic studies (Fig 2) showed a very rapid induction of histamine 
secretion from skin mast cells by complement peptides, release in-
duced by C3a and C5a, each at 10 ,liM, reaching maxima of 10.9 ± 
0.8% and 22.4 ± 2.2% of cellular histamine respectively at 15 sec-
onds. 
To investigate whether or not complement peptides also stimu-
late the generation of newly generated mast cell mediators, the 
release ofPGD2 was examined in three experiments in which spon-
taneous histamine release was 5.3 ± 0.5% and that of PGD2 was 
4.9 ± 0.3 ng/l06 mast cells. The net amounts of histamine and 
PGD2 released by 3% anti-lgE were 14.2 ± 0 .2% and 22.6 ± 0.2 
ng/l06 mast cells, respectively. Although histamine releases in-
duced by 10 ,liM C3a and 1 liM C5a were comparable in being 
9.7 ± 1.1 % and 14.8 ± 1.2%, respectively, the net releases ofPGD2 
were only 3.5 ± 0 .9 and 4.9 ± 0.5 ng/l06 mast cells . These results 
indicate that, like neuropeptides [29]. complement peptides induce 
the preferential release of preformed mast cell mediators. 
Calcium and Energy Dependence of Histamine Release To 
assess the importance of extracellular calcium in activation-secre-
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Figure 2. Time-course of histamine release induced by 10,uM C3a (II) and 
10 J.1.M CSa (e). Results are expressed as mean ± SEM of three experiments 
in which spontaneous histamine release was 4.8 ± 1.5%. 
tion coupling, human skin mast cells were stimulated with C3a and 
CSa in the presence and absence of2 mM EDTA. The results from 
three experiments, in which spontaneous histamine release was 
2.9 ± 1.6%, showed that calcium chelation had no significant ef-
fects on preformed mediator secretion, histamine releases in the 
absence and presence of EDT A being 10.9 ± 0.6% and 9.8 ± 0.4%, 
respectively, for 10 ,uM C3a and 12.4 ± 0.6% and 11.4 ± 1.3%, 
respectively, for 10,uM C5a. 
To determine whether histamine release from human skin mast 
cells induced by C3a and C5a is an energy-dependent process, four 
experiments were undertaken in which cellular glycolysis was in-
hibited by 2-deoxy-D-glucose and oxidative phosphorylation by 
antimycin A. Spontaneous histamine release in these experiments 
was 3.7 ± 0.9%. The metabolic inhibitors reduced histamine re-
lease by both anaphylatoxins by more than 95%, the net release 
induced by 10,uC3a being reduced from 8.2 ± 1.1 % to 0.4 ± 0.1 %, 
whereas that induced by O.l,LlM C5a was reduced from 8.3 ± 0.6% 
to 0.3 ± 0.1 % by incubation with inhibitors. 
Antagonism of Histamine Release by SPA As the characteris-
tics of histamine release from human skin mast cells induced by 
complement anaphylatoxins were shown to be similar to those in-
duced by substance P in terms of concentration response, time 
course, calcium deprivation, and PGDz generation l29,30], the 
hypoth esis that they may interact with the same cell membrane 
activation site was considered. This was tested by the use of 
[D-Pro4, Trp7,9,1O] SP 4-11 (SPA), a competitive inhibitor of sub-
stance P - induced histamine release. The results (Fig 3) show that 
histamine release induced by 30,uM substance P was inhibited in a 
concentration-related manner with 57.8% inhibition being ob-
served in the presence of 50 ,uM SPA. In contrast, SPA failed to 
inhibit C3a- and C5a-induced histamine release. These resu lts sug-
gest that neuropeptides and complement peptides act at distinct 
activation sites. 
Studies on the Possible Degradation of C5a by Human Mast 
Cells Because the degree of histamine release obtained by C5a 
from human skin mast cells was much lower than that reported 
from human basophils [7 ,10], we considered the possibility of C3a 
and C5a degradation to their inactive des Arg derivatives by cleav-
age of the C-terminal Arg by the carboxypeptidase known to be 
present in the MCTC subset of mast cells found in human skin 
l2,4, 13,31-33] . This was tested functionally in four experiments in 
which O.l,uM C5a or buffer (control) was incubated with mast cells 
for 1 min at 37"C before transference of an aliquot of the superna-
tant to a fresh batch of basophils preincubated at 3rc. A second 
aliquot was used to assess mast cell histamine release. The results 
show that C5a induced only 10.5 ± 0.6% histamine release from 
skin mast cells whereas the release from basophils was 40.4 ± 0.5%. 
Stimulation of basophils with the mast cell Sllpernatant resulted in 
the apparrent release of 54.7 ± 2.8% histamine, approximately the 
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equivalent of that expected from the addition of mast cell and baso-
phil releases. Human basophils were unresponsive to supernatant 
removed from buffer-challenged mas t cells. These results indicate 
that there was no overt catabolism of complement peptides, but they 
do not preclude the possibility that some degradation may occur in 
the microenvironment around the mast cell thus reducing its effec-
tive concentration at a cell-surface activation site. 
DISCUSSION 
Intradermal injection of picomolar concentrations of the comple-
ment ana phyla toxins elicit a rapid wheal and flare reaction in 
human skin that begins within seconds of injection and lasts for 
60-70 min with C5a being some 50 times more potent than C3a 
[14,21]. Electron microscopical examination of skin biopsies show-
ing mast cell degranulation shortly after injection of C5a and C3a is 
suggestive of an interaction of complement peptides with mast cells 
[14,15]. Our experiments with human dispersed skin mast cells, like 
those of Kubota [22], provide evidence that mast cells may be acti-
vated directly fo llowing stimulation with the complement anaphy-
latoxins, the time course of histamine release and the potency dif-
ference between the peptides, 40-50 fold, correlating with the 
clinical observations. The activation of skin mast cells by CSa con-
trasts to rel?orts that human lung mast cells are refractory to this 
peptide [10j , suggesting a heterogeneity of responsiveness between 
mast cell populations. A similar heterogeneity has been observed 
with substance P, vasoactive intestinal peptide (VIP), somatostatin, 
compound 48/80, and skin mast cells, but not those from the lungs, 
adenoids, and tonsils , these being responsive to these secretagogues 
[34]. 
The characteristics of mediator release induced by C3a and C5a 
have many characteristics in C0111mon with that induced by sub-
stance P and related basic polypeptides. First, the time course is 
rapid, release being complete within 15 seconds [30] . Second, al-
though release requires adenosine triphosphate (ATP) and oxidative 
phosphorylation, it is independent of the presence of extracellular 
calcium suggesting that the mobilization of intracellular calcium 
provides sufficient levels of the cation necessary for activation-
secretion coupling [35] . Third, there is negligible generation of the 
newly formed mediator, PGDz [29]. Studies with substance P have 
shown activation of a pertussis toxin sensitive G-protein to be an 
early process in activation-secretion coupling [36,37]. The similari-
ties with substance P - induced activation suggest that complement 
pep tides may also activate a mast cell membrane-associated G-pro-
tein, a hypothesis supported by the observations that pertussis toxin 
treatment reduces C5a-induced histamine secretion from human 
basophils [8] and C5a-induced GTPase ac tivity in rabbit neutrophil 
plasma membranes [38]. 
Studies with a wide range of lipophilic peptides, including sub-
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Figure 3. Effect of SPA on histamine release from human dispersed skin 
mast ce lls induced by 30,uM substance P (ll), l,uM C3a (11) , 1,uM CSa (_), 
or in the absence of secretagogue (\7). Results are expressed as mean ± SEM 
of four experiments in which spontaneous histamine release was 4.1 ±0.9%. 
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suggest that a basic N-terminal is necessary ~or histamine release. 
Indeed, the sequential removal of the N-termm~l Arg-Pro-Lys-Pro 
from substance P results in a gradual loss of aCtlvlty [41] . As C3a and 
C5a are also basic peptides with a C-terminal Arg and as cleavage of 
this terminal to yield C3a des Arg and C5a des Arg leads to loss of 
activity, we suspected that the anaph'ylatox~ns may interact with th
4
e 
same activation site as the other baSIC pepttdes. However, [D-Pro , 
D-T rp7.9.10] SP 4- 11 (SPA) which has been shown previously to act as 
a competitive antago111st of hlstamme release mduce~ by all the 
basic compounds previously tested [30,42], failed to mhlblt C3a- or 
C5a-induced histamine release suggesting that complement pep-
tides act at membrane activation site distinct from that with which 
other basic peptides interact. Whether or not this activation site is 
true like the high-affinity receptors on guinea-pig platelet mem-
branes [43] or human polymorphonuclear leucocytes [44] has yet to 
be determined . 
In conclusion, the results presented here demonstrated that bo~h 
C3a and C5a induce a rapid release of histamine from human skm 
mast cells with C5a being more potent. Removal of the functionally 
essential arginine from the carboxyl-terminal of C3a and C5a sig-
nificantly reduced the histamine-releasing capacity. The character-
istics of mediator release from skin mast cells in response to C3a and 
C5a is similar to that induced by substance P in that it displays rapid 
kinetics, is independent of extracellular calcium, and has histamine 
release accompanied by negligible PGD2 generation. However, 
studies with the substance P antagonist SPA suggest that the activa-
tion site for anaphylatoxins is distinct from that of neuropeptides 
and other basic secretagogues. 
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